TW593315B - Substituted pyridines and pyridazines with angiogenesis inhibiting activity - Google Patents

Substituted pyridines and pyridazines with angiogenesis inhibiting activity Download PDF

Info

Publication number
TW593315B
TW593315B TW089119700A TW89119700A TW593315B TW 593315 B TW593315 B TW 593315B TW 089119700 A TW089119700 A TW 089119700A TW 89119700 A TW89119700 A TW 89119700A TW 593315 B TW593315 B TW 593315B
Authority
TW
Taiwan
Prior art keywords
methyl
amino
oxy
furo
group
Prior art date
Application number
TW089119700A
Other languages
English (en)
Chinese (zh)
Inventor
Jacques P Dumas
Stephen James Boyer
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW593315B publication Critical patent/TW593315B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
TW089119700A 1999-09-28 2000-09-25 Substituted pyridines and pyridazines with angiogenesis inhibiting activity TW593315B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
TW593315B true TW593315B (en) 2004-06-21

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089119700A TW593315B (en) 1999-09-28 2000-09-25 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Country Status (35)

Country Link
EP (1) EP1228063B1 (enExample)
JP (1) JP4919567B2 (enExample)
KR (3) KR100895571B1 (enExample)
CN (3) CN100422173C (enExample)
AR (3) AR025752A1 (enExample)
AT (1) ATE422494T1 (enExample)
AU (1) AU782820B2 (enExample)
BG (1) BG65860B1 (enExample)
BR (1) BRPI0014382B8 (enExample)
CA (1) CA2385817C (enExample)
CO (1) CO5200835A1 (enExample)
CZ (1) CZ304767B6 (enExample)
DE (1) DE60041548D1 (enExample)
DO (1) DOP2000000070A (enExample)
EE (1) EE05258B1 (enExample)
ES (1) ES2320525T3 (enExample)
GT (1) GT200000158A (enExample)
HR (1) HRP20020308A2 (enExample)
HU (1) HU230223B1 (enExample)
IL (3) IL148880A0 (enExample)
MA (1) MA25563A1 (enExample)
MX (1) MXPA02003156A (enExample)
MY (3) MY143580A (enExample)
NO (1) NO20021520L (enExample)
NZ (1) NZ518589A (enExample)
PA (1) PA8503201A1 (enExample)
PE (1) PE20010607A1 (enExample)
PL (1) PL205957B1 (enExample)
RS (1) RS50369B (enExample)
RU (1) RU2260008C2 (enExample)
SK (1) SK287417B6 (enExample)
TW (1) TW593315B (enExample)
UA (1) UA75053C2 (enExample)
WO (1) WO2001023375A2 (enExample)
ZA (1) ZA200202760B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000874A (es) * 2000-08-09 2003-06-06 Astrazeneca Ab Compuestos quimicos.
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
DE602004019193D1 (de) * 2003-03-11 2009-03-12 Novartis Ag Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
CN107129502B (zh) 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3959214A1 (en) * 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
NZ290952A (en) * 1994-08-09 1998-05-27 Eisai Co Ltd Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1107964B8 (en) * 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
EP1165085B1 (en) * 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Also Published As

Publication number Publication date
CZ20021444A3 (cs) 2002-08-14
BG65860B1 (bg) 2010-03-31
EE200200161A (et) 2003-08-15
JP2003526632A (ja) 2003-09-09
CN100422172C (zh) 2008-10-01
BR0014382A (pt) 2003-06-24
PL366342A1 (en) 2005-01-24
BG106637A (bg) 2003-02-28
PL205957B1 (pl) 2010-06-30
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
DE60041548D1 (de) 2009-03-26
IL148880A0 (en) 2002-09-12
KR20080086547A (ko) 2008-09-25
WO2001023375A2 (en) 2001-04-05
WO2001023375A3 (en) 2002-05-02
CO5200835A1 (es) 2002-09-27
PA8503201A1 (es) 2002-08-26
HUP0202704A3 (en) 2003-12-29
EP1228063B1 (en) 2009-02-11
IL193368A0 (en) 2009-02-11
HRP20020308A2 (en) 2004-06-30
AR025752A1 (es) 2002-12-11
AR082232A2 (es) 2012-11-21
SK5912002A3 (en) 2003-01-09
NO20021520L (no) 2002-05-23
MA25563A1 (fr) 2002-10-01
EE05258B1 (et) 2010-02-15
NO20021520D0 (no) 2002-03-26
KR100890473B1 (ko) 2009-03-26
AU782820B2 (en) 2005-09-01
HUP0202704A2 (hu) 2002-12-28
IL193368A (en) 2011-05-31
DOP2000000070A (es) 2002-02-28
IL193367A0 (en) 2009-02-11
KR20020038775A (ko) 2002-05-23
HK1091818A1 (zh) 2007-01-26
CA2385817C (en) 2010-05-04
MY135058A (en) 2008-01-31
MY143580A (en) 2011-05-31
HK1091819A1 (zh) 2007-01-26
GT200000158A (es) 2002-03-16
CA2385817A1 (en) 2001-04-05
KR20080091505A (ko) 2008-10-13
RS50369B (sr) 2009-11-10
UA75053C2 (en) 2006-03-15
CN100422173C (zh) 2008-10-01
CN1420879A (zh) 2003-05-28
SK287417B6 (sk) 2010-09-07
AU1569601A (en) 2001-04-30
AR082231A2 (es) 2012-11-21
KR100895571B1 (ko) 2009-04-29
ATE422494T1 (de) 2009-02-15
BR0014382B1 (pt) 2014-04-01
PE20010607A1 (es) 2001-07-12
MY143377A (en) 2011-05-13
IL193367A (en) 2011-03-31
HU230223B1 (en) 2015-10-28
ES2320525T3 (es) 2009-05-25
NZ518589A (en) 2005-03-24
BRPI0014382B8 (pt) 2021-05-25
YU22902A (sh) 2004-12-31
RU2260008C2 (ru) 2005-09-10
KR100895572B1 (ko) 2009-04-29
CN100374435C (zh) 2008-03-12
HRP20020308B1 (enExample) 2013-01-31
MXPA02003156A (es) 2002-09-30
JP4919567B2 (ja) 2012-04-18
CZ304767B6 (cs) 2014-10-08
CN1769283A (zh) 2006-05-10
ZA200202760B (en) 2003-10-29

Similar Documents

Publication Publication Date Title
TW593315B (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
TW477788B (en) Substituted heteroaromatic compounds and their methods for their preparation and use
US8680139B2 (en) Anti-neoplastic compounds, compositions and methods
CN102741256B (zh) 对于蛋白激酶具有抑制活性的双环杂芳基衍生物
KR100226114B1 (ko) 항증식 작용을 가진 퀴나졸린 화합물
US10562912B2 (en) Heterocyclic derivatives and use thereof
JP5948352B2 (ja) 新規なスルホンアミノキノリン系ヘプシジン拮抗薬
JP5216341B2 (ja) 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
TW200914443A (en) Process for preparing substituted quinazolinyl furanaldehyde
TWI301834B (en) Pyrimidone compound and pharmaceutical composition including the same
WO2001087845A2 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
US20070281936A1 (en) Pyrimidine Compounds as Purine Receptor Antagonist
TW201113272A (en) Novel pyrimidine-and triazine hepcidine antagonists
JPWO2010058846A1 (ja) 4,6−ジアミノニコチンアミド化合物
AU2005317870A1 (en) Pyridine carboxamide derivatives for use as anticancer agents
TW200526593A (en) New pyridazin-3(2H)-one derivatives
WO2006036024A1 (ja) プロトンポンプ阻害薬
JP2011507894A (ja) プロリルヒドロキシラーゼ阻害剤
WO2010072166A1 (zh) 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
AU2018226922B2 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
CA2990583A1 (en) 1,4-disubstituted imidazole derivative
TW201040159A (en) Novel compound having 4-pyridylalkylthio group as substituent
CA3093323C (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
KR20020019969A (ko) 혈관신생 억제 활성을 갖는 치환 피리다진 및 융합 피리다진
JP2022514685A (ja) ペンタミジンの類似体及びその使用

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent